Bankers are putting together major financing packages in preparation of a potential private equity bid for GlaxoSmithKline’s consumer healthcare business, according to reports.
Lenders are reportedly modelling debt packages of between £20bn and £25bn in sterling, dollars and euro, according to Bloomberg, after it emerged that GSK had rebuffed three cash-and-share approaches from Marmite-maker Unilever last year.
Analysts have said that Unilever’s offer has put GSK’s consumer group in the shop window and a number of other consumer firms will be sizing up the business as a potential fit.
Read more/Source: City AM
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.